BMP2 and Miyoshi myopathy: Particularly, the variant BMP2-KD, which exhibited increased osteogenic potential and improved Activin A-inhibiting characteristics compared to wildtype BMP2, appeared beneficial for the treatment of the major symptoms in MM.